AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 80275 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin (15 mg/m2 weekly)
Number of subjects: 27
Study 31944127 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio Processor Satisfaction Questionnaire (APSQ)
Number of subjects: 69
Study 31533379 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenotomy
Number of subjects: 40
Study 31533379 — intervention group
Group type: COMPARATOR
Intervention: Tenodesis
Number of subjects: 40
Study 27987221 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 27
Study 27987221 — intervention group
Group type: COMPARATOR
Intervention: Placebo rTMS
Number of subjects: 27
Study 26502714 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate‐amodiaquine (AA)
Number of subjects: 248
Study 26502714 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether‐lumefantrine (AL)
Number of subjects: 248
Study 26502714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AA and AL
Number of subjects: 248
Study 23810029 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up (n=282)
Number of subjects: 559
Study 23810029 — intervention group
Group type: COMPARATOR
Intervention: Mail questionnaire (n=277)
Number of subjects: 559
Study 21060109 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX184 5 mg
Number of subjects: 8
Study 21060109 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX184 10 mg
Number of subjects: 8
Study 21060109 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX184 25 mg
Number of subjects: 8
Study 21060109 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX184 50 mg
Number of subjects: 8
Study 21060109 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX184 75 mg
Number of subjects: 8
Study 21060109 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX184 100 mg
Number of subjects: 8
Study 21060109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 19597358 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐Focused Exposure Therapy
Number of subjects: 30
Study 19597358 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive and behavioral method
Number of subjects: 30
Study 17313720 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation at 15 mg/d for 6 months
Number of subjects: 387
Study 17313720 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation at 30 mg/d for 6 months
Number of subjects: 387
Study 17313720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study 15108100 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B oral suspension
Number of subjects: 40
Study 15108100 — intervention group
Group type: COMPARATOR
Intervention: Nystatin oral suspension
Number of subjects: 40
Study 11772795 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 45
Study 11772795 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 45
Study 11772795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 9690694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mCPP (0.1 mg/kg)
Number of subjects: 14
Study 9690694 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mCPP (0.5 mg/kg)
Number of subjects: 14
Study 9690694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7861714 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day s.c. of recombinant human growth hormone (rhGH) during the treatment period
Number of subjects: 10
Study 2524603 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxisylyte
Number of subjects: 170
Study 2524603 — intervention group
Group type: COMPARATOR
Intervention: Papaverine
Number of subjects: 170
Study 393464 — intervention group
Group type: EXPERIMENTAL
Intervention: fenbufen (800 mg/day)
Number of subjects: 29
Study 393464 — intervention group
Group type: COMPARATOR
Intervention: indomethacin (100 mg/day)
Number of subjects: 29
Study 31011865 — intervention group
Group type: EXPERIMENTAL
Intervention: Real 850-nm PBM by LED array on the right prefrontal cortex
Number of subjects: 30
Study 31011865 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study 28153927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 27
Study 28153927 — intervention group
Group type: COMPARATOR
Intervention: Computer skills training (CST) placebo
Number of subjects: 27
Study 26482669 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy screen visible to the instructor
Number of subjects: 206
Study 26482669 — intervention group
Group type: COMPARATOR
Intervention: Control group (videolaryngoscope screen covered)
Number of subjects: 206
Study 26482669 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy with premedication
Number of subjects: 206
Study 26482669 — intervention group
Group type: COMPARATOR
Intervention: Control group with premedication (screen covered)
Number of subjects: 206
Study 23679192 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene 120 mg (TOR120)
Number of subjects: 91
Study 23679192 — intervention group
Group type: COMPARATOR
Intervention: Exemestane 25 mg (EXE)
Number of subjects: 91
Study 22095792 — intervention group
Group type: EXPERIMENTAL
Intervention: rLH
Number of subjects: 244
Study 22095792 — intervention group
Group type: COMPARATOR
Intervention: Control (rFSH alone)
Number of subjects: 244
Study 20952373 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment (e.g., statins)
Number of subjects: 0
Study 20952373 — intervention group
Group type: EXPERIMENTAL
Intervention: Low total cholesterol (<5.5 mmol/l)
Number of subjects: 0
Study 20952373 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment (statins)
Number of subjects: 0
Study 18020846 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-focused group intervention (CG) for women with early stage breast cancer, 6 sessions
Number of subjects: 238
Study 18020846 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-focused group intervention (CG)
Number of subjects: 238
Study 18020846 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 238
Study 16132121 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant-supplemented beverage (30 ml.kg(‐1) pre-exercise and during exercise)
Number of subjects: 26
Study 16132121 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 ml.kg(‐1) pre-exercise and during exercise)
Number of subjects: 26
Study 12189360 — intervention group
Group type: EXPERIMENTAL
Intervention: nelfinavir
Number of subjects: 176
Study 12189360 — intervention group
Group type: EXPERIMENTAL
Intervention: indinavir
Number of subjects: 176
Study 12189360 — intervention group
Group type: COMPARATOR
Intervention: saquinavir
Number of subjects: 176
Study 10434218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.15 or 0.2 mg/kg)
Number of subjects: 40
Study 10434218 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium (0.9 or 1.2 mg/kg)
Number of subjects: 40
Study 7843700 — intervention group
Group type: COMPARATOR
Intervention: Interferon (IFN) therapy for 6 months (3 to 5 million units three times a week)
Number of subjects: 80
Study 7843700 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) plus Ursodeoxycholic acid (UDCA) therapy for 6 months (IFN) and 3 additional months (UDCA 10 mg/kg/d)
Number of subjects: 80
Study 7843700 — intervention group
Group type: COMPARATOR
Intervention: Interferon (IFN) therapy
Number of subjects: 80
Study 7843700 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) plus Ursodeoxycholic acid (UDCA) therapy
Number of subjects: 80
Study 2222595 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized isoetharine
Number of subjects: 52
Study 2222595 — intervention group
Group type: COMPARATOR
Intervention: Basic life support only (Control)
Number of subjects: 52
Study 6993163 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy during pregnancy
Number of subjects: 615
Study 6993163 — intervention group
Group type: COMPARATOR
Intervention: Control group (no insulin therapy)
Number of subjects: 615
Study 31884472 — intervention group
Group type: EXPERIMENTAL
Intervention: T3D-959 (3, 10, 30, or 90 mg daily for 14 days)
Number of subjects: 34
Study 31796480 — intervention group
Group type: EXPERIMENTAL
Intervention: QinTB smartphone application
Number of subjects: 400
Study 31796480 — intervention group
Group type: COMPARATOR
Intervention: Doctors' advice
Number of subjects: 400
Study 28347654 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75mg every 2 weeks (Q2W)
Number of subjects: 517
Study 28347654 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150mg Q2W (for those with LDL-C≥70mg/dL at week 8)
Number of subjects: 517
Study 28347654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 517
Study 25758408 — intervention group
Group type: EXPERIMENTAL
Intervention: Six 1‐h circuit classes targeting balance over a 2‐week period in addition to usual therapy
Number of subjects: 162
Study 25758408 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy
Number of subjects: 162
Study 22588577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral sex therapy
Number of subjects: 31
Study 22588577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral sex therapy with ginkgo biloba
Number of subjects: 31
Study 22588577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral sex therapy without ginkgo biloba
Number of subjects: 31
Study 21834061 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 505
Study 21834061 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX in combination with TNF inhibitors
Number of subjects: 505
Study 21834061 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF inhibitors as monotherapy
Number of subjects: 505
Study 21834061 — intervention group
Group type: COMPARATOR
Intervention: Control group (SpA patients receiving NSAIDs/analgesics)
Number of subjects: 505
Study 21834061 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant prednisolone treatment
Number of subjects: 505
Study 19726822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic high‐osmolar radiographic contrast agent diatrizoate (Group A)
Number of subjects: 44
Study 19726822 — intervention group
Group type: COMPARATOR
Intervention: Non‐ionic iso‐osmolar contrast agent iodixanol (Group B)
Number of subjects: 44
Study 17461857 — intervention group
Group type: EXPERIMENTAL
Intervention: Alovudine 2 mg/day
Number of subjects: 72
Study 17461857 — intervention group
Group type: EXPERIMENTAL
Intervention: Alovudine 1 mg/day
Number of subjects: 72
Study 17461857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 15651747 — intervention group
Group type: COMPARATOR
Intervention: stavudine/didanosine/efavirenz (group A)
Number of subjects: 161
Study 15651747 — intervention group
Group type: COMPARATOR
Intervention: zidovudine/lamivudine/nelfinavir (group B)
Number of subjects: 161
Study 15651747 — intervention group
Group type: EXPERIMENTAL
Intervention: alternating regimen (group C)
Number of subjects: 161
Study 11269571 — intervention group
Group type: EXPERIMENTAL
Intervention: RG 12525 100 mg qd for 4 days
Number of subjects: 0
Study 11269571 — intervention group
Group type: EXPERIMENTAL
Intervention: RG 12525 600 mg qd for 4 days
Number of subjects: 0
Study 11269571 — intervention group
Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 0
Study 9051276 — intervention group
Group type: EXPERIMENTAL
Intervention: Information-eliciting strategies (interviewing styles and question types)
Number of subjects: 80
Study 9051276 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of body-related attitudes
Number of subjects: 80
Study 7958164 — intervention group
Group type: EXPERIMENTAL
Intervention: buserelin (1.2 mg/day, intranasally for 3 months)
Number of subjects: 12
Study 2885599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg daily for the first week, tapering off over 2 weeks)
Number of subjects: 78
Study 2885599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 2885599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 78
Study 28497396 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Training (PMRT)
Number of subjects: 60
Study 28497396 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Training (PMRT) plus Chinese Medicine Five-Element Music Therapy
Number of subjects: 60
Study 28497396 — intervention group
Group type: COMPARATOR
Intervention: Control group (PMRT only)
Number of subjects: 60
Study 27543208 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 230
Study 27543208 — intervention group
Group type: EXPERIMENTAL
Intervention: MI intervention with HealthCall
Number of subjects: 230
Study 27543208 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention
Number of subjects: 230
Study 27543208 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory outcomes (drinking frequency, binge frequency, maximum quantity)
Number of subjects: 230
Study 23538559 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 45
Study 23687260 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 606
Study 23687260 — intervention group
Group type: COMPARATOR
Intervention: INX
Number of subjects: 606
Study 21208550 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted split H1N1 vaccine
Number of subjects: 347
Study 21208550 — intervention group
Group type: COMPARATOR
Intervention: Whole-virion (WV) vaccine
Number of subjects: 347
Study 18188748 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco-free snuff
Number of subjects: 106
Study 18188748 — intervention group
Group type: COMPARATOR
Intervention: No snuff
Number of subjects: 106
Study 16157857 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace only
Number of subjects: 67
Study 16157857 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 67
Study 16157857 — intervention group
Group type: COMPARATOR
Intervention: Combination brace and physical therapy
Number of subjects: 67
Study 11955605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implant children
Number of subjects: 240
Study 11955605 — intervention group
Group type: COMPARATOR
Intervention: Normal-hearing children
Number of subjects: 240
Study 9917226 — intervention group
Group type: EXPERIMENTAL
Intervention: L-754,030 (400 mg before cisplatin and 300 mg on days 2 to 5)
Number of subjects: 159
Study 9917226 — intervention group
Group type: EXPERIMENTAL
Intervention: L-754,030 (400 mg before cisplatin and placebo on days 2 to 5)
Number of subjects: 159
Study 9917226 — intervention group
Group type: COMPARATOR
Intervention: Placebo (before cisplatin and placebo on days 2 to 5)
Number of subjects: 159
Study 7793188 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 74
Study 7793188 — intervention group
Group type: COMPARATOR
Intervention: Thiamylal-isoflurane
Number of subjects: 74
Study 1962596 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 20 mg once a day
Number of subjects: 94
Study 1962596 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg once a day
Number of subjects: 94
Study 1962596 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 80 mg once a day
Number of subjects: 94
Study 1962596 — intervention group
Group type: EXPERIMENTAL
Intervention: Droloxifene 120 mg once a day (pilot study)
Number of subjects: 94
Study 7060371 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 μg norethisterone (NET) minipill
Number of subjects: 24
Study 7060371 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg of ethinylestradiol for 7 days
Number of subjects: 24
Study 7060371 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 24
Study 7060371 — intervention group
Group type: EXPERIMENTAL
Intervention: norethisterone
Number of subjects: 24
Study 30396772 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso-osmolar oral supplement (279 mOsm/kg)
Number of subjects: 8
Study 30396772 — intervention group
Group type: COMPARATOR
Intervention: Hyperosmolar oral supplement (681 mOsm/kg)
Number of subjects: 8
Study 28235537 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane 4.1% with remifentanil 1ng/ml (R1 group)
Number of subjects: 42
Study 28235537 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane 3.4% with remifentanil 3ng/ml (R3 group)
Number of subjects: 42
Study 28235537 — intervention group
Group type: COMPARATOR
Intervention: R1 group (1ng/ml of remifentanil)
Number of subjects: 42
Study 28235537 — intervention group
Group type: COMPARATOR
Intervention: R3 group (3ng/ml of remifentanil)
Number of subjects: 42
Study 27923389 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow infusion of 5% albumin (180 minutes) at a dose of 10 ml/kg ideal body weight
Number of subjects: 70
Study 27923389 — intervention group
Group type: COMPARATOR
Intervention: Rapid infusion of 5% albumin (30 minutes) at a dose of 10 ml/kg ideal body weight
Number of subjects: 70
Study 27923389 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rapid and slow infusion of 5% albumin
Number of subjects: 70
Study 24438432 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for 4 weeks
Number of subjects: 70
Study 22374642 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 units/kg aspart
Number of subjects: 8
Study 22374642 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 units/kg detemir
Number of subjects: 8
Study 22374642 — intervention group
Group type: COMPARATOR
Intervention: Separate injection of aspart and detemir
Number of subjects: 8
Study 22374642 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed injection of aspart and detemir
Number of subjects: 8
Study 19319701 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antiepileptic drugs (AEDs) initiated in 23 patients (8%) without documented seizure during the first 10 days of the trial.
Number of subjects: 295
Study 19319701 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group from the Cerebral Hemorrhage and NXY‐059 Trial).
Number of subjects: 295
Study 17000884 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 1.0 mg/kg every 12 hours for 5 days, followed by 1.0 mg/kg daily for 175 days
Number of subjects: 122
Study 17000884 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 1.0 mg/kg every 12 hours for at least 5 days followed by warfarin (stable INR of 2 to 3)
Number of subjects: 122
Study 12491503 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m(2)) followed by paclitaxel (175 mg/m(2) 3‐hour infusion; AT)
Number of subjects: 275
Study 12491503 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin-cyclophosphamide regimen (AC; 60/600 mg/m(2))
Number of subjects: 275
Study 10664499 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOC (60 g for initial transfusion, with options for three more doses of 30 g each within 96 hours)
Number of subjects: 72
Study 10664499 — intervention group
Group type: COMPARATOR
Intervention: Allogenic RBC transfusion (standard RBC transfusions)
Number of subjects: 72
Study 10664499 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOC
Number of subjects: 72
Study 10664499 — intervention group
Group type: COMPARATOR
Intervention: Allogenic RBC
Number of subjects: 72
Study 9038445 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 36
Study 9038445 — intervention group
Group type: COMPARATOR
Intervention: 35% oxygen by facemask
Number of subjects: 36
Study 1736766 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt containing Lactobacillus acidophilus
Number of subjects: 21
Study 1736766 — intervention group
Group type: COMPARATOR
Intervention: Yogurt-free diet (Control)
Number of subjects: 21
Study 6238910 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg/day)
Number of subjects: 0
Study 6238910 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe restriction of salt intake (about 1016 mg Na+/day)
Number of subjects: 0
Study 6238910 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied to be no treatment during initial 2 weeks)
Number of subjects: 0
Study 31467047 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternity waiting home (MWH) use
Number of subjects: 3784
Study 31467047 — intervention group
Group type: EXPERIMENTAL
Intervention: Housewives
Number of subjects: 3784
Study 31467047 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with companions for facility visits
Number of subjects: 3784
Study 31467047 — intervention group
Group type: EXPERIMENTAL
Intervention: Wealthier households (fourth vs first quintile)
Number of subjects: 3784
Study 31467047 — intervention group
Group type: EXPERIMENTAL
Intervention: Women living >30 min from a health facility
Number of subjects: 3784
Study 31467047 — intervention group
Group type: EXPERIMENTAL
Intervention: Education, decision-making autonomy, community-level institutional births
Number of subjects: 3784
Study 29901599 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape applied from origin to insertion
Number of subjects: 18
Study 29901599 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape applied from insertion to origin
Number of subjects: 18
Study 29901599 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 18
Study 27125273 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal polysaccharide nontypeable Haemophilus influenzae protein D-conjugated vaccine (PHiD-CV)
Number of subjects: 5093
Study 27125273 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (hepatitis B)
Number of subjects: 5093
Study 24767554 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveOne (Dentsply Maillefer)
Number of subjects: 48
Study 24767554 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc (VDW)
Number of subjects: 48
Study 24767554 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper (Dentsply Maillefer)
Number of subjects: 48
Study 24767554 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo (VDW)
Number of subjects: 48
Study 22285545 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoFoam bupivacaine 133 mg
Number of subjects: 138
Study 22285545 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoFoam bupivacaine 266 mg
Number of subjects: 138